Novo Nordisk Investor Presentation - First Nine Months of 2016
Investor presentation
First nine months of 2016
Slide 84
Competitive US label for SaxendaⓇ
SaxendaⓇ approved in the US for chronic weight management in individuals with a BMI ≥30,
or ≥27 in the presence of at least one weight-related comorbidity¹
Profile
GLP-1 receptor agonist - a physiological regulator of appetite and calorie intake
SaxendaⓇ is the first and only GLP-1 receptor agonist approved for weight management
Effect on body
weight
Effect on
comorbidities
Safety
•
9 in 10 lose weight and 1 in 3 people lose more than 10% of their body weight²
Average weight loss of 9.2% in completers at one year²
Improvements in cardiometabolic risk factors such as hypertension and dyslipidaemia
Boxed warning on thyroid C-cell tumours
Precautions on acute pancreatitis, acute gallbladder disease, serious hypoglycaemia³, heart rate increase,
renal impairment, hypersensitivity and suicidal ideation
1 Examples include hypertension, type 2 diabetes and dyslipidemia 2 SaxendaⓇ US Package Information. 3 When used with an insulin secretagogue
changing
diabetes®
novo nordiskView entire presentation